Clinical Trials Logo

Recurrent Hematologic Malignancy clinical trials

View clinical trials related to Recurrent Hematologic Malignancy.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03739606 Withdrawn - Acute Leukemia Clinical Trials

Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer

Start date: October 20, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well flotetuzumab works in treating patients with CD123 positive blood cancer that has come back or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as flotetuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.